Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology.
Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations
Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market.
BeFisetin® is Gaining the First Fisetin Ingredient SA-GRAS Certification
In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market.
Bonerge Initiates the Human Clinical Trail Plans for GlucoSober®-Dihydroberberine and BeFisetin®-Fisetin
Bonerge is excited to announce the initiation of clinical trials for its high-quality brand ingredients, including GlucoSober and BeFisetin. These trials aim to substantiate the efficacy and safety of the products, providing more reliable options for the market.
